Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | MAPT | P10636 | 2/20 | 0.81 |
| ▸ | RECQL | P46063 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | STS | P08842 | 9/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.78 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | ESR1 | P03372 | 3/20 | 0.74 |
| ▸ | CA1 | P00915 | 3/20 | 0.74 |
| ▸ | CA2 | P00918 | 3/20 | 0.74 |
| ▸ | CA9 | Q16790 | 3/20 | 0.74 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.74 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | CA4 | P22748 | 1/20 | 0.74 |
| ▸ | CA6 | P23280 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27862478 | 0.92 | HSD17B1 (0.83) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL6684274 | 0.91 | HSD17B1 (0.84) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL5677806 | 0.89 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL12441050 | 0.89 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL4570835 | 0.89 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL10079402 | 0.89 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL18658723 | 0.89 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL959954 | 0.89 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL15308964 | 0.89 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL5682139 | 0.89 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4288539-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION | Research Institute at Nationwide Children's Hospital (US) | 2023-12-13 | — | — | EP | claimed |
| WO-2023178288-A1 | COMPANION DIAGNOSTICS AND STRATEGIES FOR TREATMENT WITH AN ARYL HYDROCARBON RECEPTOR AGONIST COMPOUND | AZORA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| WO-2022082183-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF INFLAMMATORY AND METABOLIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | claimed |
| EP-3501543-A1 | METHOD FOR MANUFACTURING VAGINAL DRUG DELIVERY SYSTEMS USING A THREE DIMENSIONAL PRINTER | Delim Cosmetics & Pharma S.r.l. (IT) | 2019-06-26 | — | — | EP | claimed |
| US-20160279043-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | DENTALMED PHARM HOLDING LTD. (BE) | 2016-09-29 | — | — | US | claimed |
| US-20100312137-A1 | Ovulation Cycle Monitoring and Management | GILMOUR ROBERT | 2010-12-09 | — | — | US | claimed |
| US-20100119595-A1 | Monounsaturated fatty acids and perhydrocyclopentanophenanthrene nucleus combination molecules, and their precursors, and the use of all of these as weight-loss agents | GIROUARD MICHAEL P | 2010-05-13 | — | — | US | claimed |
| US-20090169526-A1 | BMP-6 ESTROGEN RESPONSIVE ELEMENT AND METHODS OF USE THEREOF | WYETH | 2009-07-02 | — | — | US | claimed |
| EP-1812111-A2 | METHODS OF USING FATTY-ACID ESTERS OF ESTROGENS AND THERMOGENIC COMPOUNDS FOR REDUCING THE BODY WEIGHT OF A MAMMAL AND COMPOSITIONS CONTAINING THE SAME | Oleoyl-Estrone Developments SL (ES) | 2007-08-01 | — | — | EP | claimed |
| US-20070042040-A1 | Methods and compositions using gonadotropin hormone releasing hormone | DEBIOPHARM S.A. (CH) | 2007-02-22 | — | — | US | claimed |
| CN-1780634-A | Methods and compositions using gonadotropin hormone releasing hormone | DEBIOPHARM SA (CH) | 2006-05-31 | — | — | CN | claimed |
| EP-1594481-A4 | MONOUNSATURATED FATTY ACIDS AND PERHYDROCYCLOPENTANOPHENANTHRENE NUCLEUS COMBINATION MOLECULES, AND THEIR PRECURSORS, AND THE USE OF ALL OF THESE AS WEIGHT-LOSS AGENTS | GIROUARD MICHAEL P (US) | 2006-05-17 | — | — | EP | claimed |
| WO-2006042733-A2 | METHODS OF USING FATTY-ACID ESTERS OF ESTROGENS AND THERMOGENIC COMPOUNDS FOR REDUCING THE BODY WEIGHT OF A MAMMAL AND COMPOSITIONS CONTAINING THE SAME | OLEOYL-ESTRONE DEVELOPMENTS, S.L. (ES) | 2006-04-27 | — | — | WO | claimed |
| US-20060084637-A1 | Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same | OLEOYL-ESTRONE DEVELOPMENTS SL (ES) | 2006-04-20 | — | — | US | claimed |
| EP-1617859-A1 | METHODS AND COMPOSITIONS USING GONADOTROPIN HORMONE RELEASING HORMONE | DEBIOPHARM S.A. (CH) | 2006-01-25 | — | — | EP | claimed |
| US-20050272678-A1 | BMP-6 estrogen responsive element and methods of use thereof | WYETH | 2005-12-08 | — | — | US | claimed |
| EP-1594481-A2 | MONOUNSATURATED FATTY ACIDS AND PERHYDROCYCLOPENTANOPHENANTHRENE NUCLEUS COMBINATION MOLECULES, AND THEIR PRECURSORS, AND THE USE OF ALL OF THESE AS WEIGHT-LOSS AGENTS | Girouard, Michael P. (US) | 2005-11-16 | — | — | EP | claimed |
| WO-2004096259-A1 | METHODS AND COMPOSITIONS USING GONADOTROPIN HORMONE RELEASING HORMONE | DEBIOPHARM S.A. (CH) | 2004-11-11 | — | — | WO | claimed |
| US-20040157816-A1 | Monounsaturated fatty acids and perhydrocyclopentanophenanthrene nucleus combination molecules, and their precursors, and the use of all of these as weight-loss agents | GIROUARD MICHAEL P (US) | 2004-08-12 | — | — | US | claimed |
| WO-2004045560-A2 | COMBINATION OF MONOUNSATURATED FATTY ACIDS AND ESTOGEN, AND THEIR USE | GIROUARD MICHAEL P (US) | 2004-06-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084637-A1 | Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same | CYP19A1, ELOVL3, ELOVL1 | HSD17B1 32/4885LMNA 2276/4885MAPT 3959/4885 |
| US-20160279043-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | SIRT3, NNT, SIRT1 | HSD17B1 3566/4885LMNA 4322/4885MAPT 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.